Sirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study.
What this study shows
Retrospective single-centre paediatric cohort reporting that sirolimus is effective in paediatric Evans syndrome and secondary autoimmune cytopenias. Abstract not yet indexed — effect sizes to be confirmed.
At a glance
| Evidence type | H Human study Marked H because it is direct evidence from a human clinical trial or human cohort; the code names the kind of study, not its quality -- a small, well-run trial is still H. |
| Study type | 3 - Human Observational |
| Model system | Human (paediatric retrospective cohort) |
| Journal | British Journal of Haematology |
| Year | 2026 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.1111/bjh.70795 · PMID 42655953 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Sirolimus |
| Target | mTOR |
| Model | Human |
| Effect | Reported effective for paediatric Evans syndrome and secondary autoimmune cytopenias |
In the Atlas
Related topics
More studies on this topic
Was this page useful?
Thank you. Your answer was counted anonymously.